Status:
COMPLETED
Sickle Cell Disease: A Retrospective Chart Review
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Sickle Cell Anemia
Eligibility:
All Genders
16+ years
Brief Summary
This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also inc...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype
- Patients ≥ 16 years of age
- Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old
- At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old
Exclusion
- Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period
- Patients with sickle cell trait
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
261 Patients enrolled
Trial Details
Trial ID
NCT01441375
Start Date
July 1 2011
End Date
July 1 2012
Last Update
October 18 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tulane University
New Orleans, Louisiana, United States, 70112
2
Universit of Tennessee
Memphis, Tennessee, United States, 38163